336 related articles for article (PubMed ID: 11733371)
1. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.
Kahle PJ; Neumann M; Ozmen L; Müller V; Odoy S; Okamoto N; Jacobsen H; Iwatsubo T; Trojanowski JQ; Takahashi H; Wakabayashi K; Bogdanovic N; Riederer P; Kretzschmar HA; Haass C
Am J Pathol; 2001 Dec; 159(6):2215-25. PubMed ID: 11733371
[TBL] [Abstract][Full Text] [Related]
2. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
3. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
4. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
[TBL] [Abstract][Full Text] [Related]
5. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes.
Kahle PJ; Neumann M; Ozmen L; Muller V; Jacobsen H; Spooren W; Fuss B; Mallon B; Macklin WB; Fujiwara H; Hasegawa M; Iwatsubo T; Kretzschmar HA; Haass C
EMBO Rep; 2002 Jun; 3(6):583-8. PubMed ID: 12034752
[TBL] [Abstract][Full Text] [Related]
6. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.
Fagerqvist T; Lindström V; Nordström E; Lord A; Tucker SM; Su X; Sahlin C; Kasrayan A; Andersson J; Welander H; Näsström T; Holmquist M; Schell H; Kahle PJ; Kalimo H; Möller C; Gellerfors P; Lannfelt L; Bergström J; Ingelsson M
J Neurochem; 2013 Jul; 126(1):131-44. PubMed ID: 23363402
[TBL] [Abstract][Full Text] [Related]
8. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
Mishizen-Eberz AJ; Guttmann RP; Giasson BI; Day GA; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
J Neurochem; 2003 Aug; 86(4):836-47. PubMed ID: 12887682
[TBL] [Abstract][Full Text] [Related]
9. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.
Sharon R; Bar-Joseph I; Frosch MP; Walsh DM; Hamilton JA; Selkoe DJ
Neuron; 2003 Feb; 37(4):583-95. PubMed ID: 12597857
[TBL] [Abstract][Full Text] [Related]
10. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease.
Campbell BC; McLean CA; Culvenor JG; Gai WP; Blumbergs PC; Jäkälä P; Beyreuther K; Masters CL; Li QX
J Neurochem; 2001 Jan; 76(1):87-96. PubMed ID: 11145981
[TBL] [Abstract][Full Text] [Related]
11. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
Kahle PJ; Neumann M; Ozmen L; Muller V; Jacobsen H; Schindzielorz A; Okochi M; Leimer U; van Der Putten H; Probst A; Kremmer E; Kretzschmar HA; Haass C
J Neurosci; 2000 Sep; 20(17):6365-73. PubMed ID: 10964942
[TBL] [Abstract][Full Text] [Related]
12. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.
Sampathu DM; Giasson BI; Pawlyk AC; Trojanowski JQ; Lee VM
Am J Pathol; 2003 Jul; 163(1):91-100. PubMed ID: 12819014
[TBL] [Abstract][Full Text] [Related]
14. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.
Hashimoto M; Rockenstein E; Mante M; Crews L; Bar-On P; Gage FH; Marr R; Masliah E
Gene Ther; 2004 Dec; 11(23):1713-23. PubMed ID: 15483670
[TBL] [Abstract][Full Text] [Related]
15. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
[TBL] [Abstract][Full Text] [Related]
16. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
17. Transmission of Soluble and Insoluble α-Synuclein to Mice.
Jones DR; Delenclos M; Baine AT; DeTure M; Murray ME; Dickson DW; McLean PJ
J Neuropathol Exp Neurol; 2015 Dec; 74(12):1158-69. PubMed ID: 26574670
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
19. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
20. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
Zhou W; Milder JB; Freed CR
J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
